ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.068,21
0,26%
S&P 500
5.439,80
0,15%
Dow Jones
38.583,42
-0,01%
Euro vs US Dollar
1,07179
0,00%
Bitcoin
65.274,60
-2,05%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Universe Pharmaceuticals Inc (UPC)

  7. Universe Pharmaceuticals Inc (UPC) News

UPC

Universe Pharmaceuticals (UPC)

Universe Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:UPC
DatumZeitQuelleÜberschriftSymbolFirma
10/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:UPCUniverse Pharmaceuticals Inc
14/05/202422h06Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:UPCUniverse Pharmaceuticals Inc
07/02/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:UPCUniverse Pharmaceuticals Inc
30/01/202422h30PR Newswire (US)Universe Pharmaceuticals INC Reports Fiscal Year 2023 Financial ResultsNASDAQ:UPCUniverse Pharmaceuticals Inc
30/01/202418h05Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:UPCUniverse Pharmaceuticals Inc
31/08/202322h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:UPCUniverse Pharmaceuticals Inc
16/08/202322h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:UPCUniverse Pharmaceuticals Inc
04/08/202314h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:UPCUniverse Pharmaceuticals Inc
04/08/202314h30GlobeNewswire Inc.Universe Pharmaceuticals INC Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Publicly Held SharesNASDAQ:UPCUniverse Pharmaceuticals Inc
27/07/202322h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:UPCUniverse Pharmaceuticals Inc
27/07/202316h15GlobeNewswire Inc.Universe Pharmaceuticals INC Announces Share ConsolidationNASDAQ:UPCUniverse Pharmaceuticals Inc
05/07/202322h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:UPCUniverse Pharmaceuticals Inc
24/05/202322h30Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:UPCUniverse Pharmaceuticals Inc
05/05/202322h16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:UPCUniverse Pharmaceuticals Inc
07/03/202314h00GlobeNewswire Inc.Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:UPCUniverse Pharmaceuticals Inc
14/02/202320h15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:UPCUniverse Pharmaceuticals Inc
10/02/202322h58Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:UPCUniverse Pharmaceuticals Inc
21/12/202214h00GlobeNewswire Inc.Universe Pharmaceuticals INC Announces Inclusion of Six Products into the First Edition of Catalogue of Medicine for Patients Infected with COVID-19NASDAQ:UPCUniverse Pharmaceuticals Inc
14/11/202214h03Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:UPCUniverse Pharmaceuticals Inc
14/11/202214h00GlobeNewswire Inc.Universe Pharmaceuticals INC Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:UPCUniverse Pharmaceuticals Inc
27/10/202222h11Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:UPCUniverse Pharmaceuticals Inc
28/09/202214h00Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:UPCUniverse Pharmaceuticals Inc
16/08/202222h16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:UPCUniverse Pharmaceuticals Inc
16/08/202214h00PR Newswire (US)Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2022NASDAQ:UPCUniverse Pharmaceuticals Inc
19/07/202222h07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:UPCUniverse Pharmaceuticals Inc
19/07/202212h00GlobeNewswire Inc.Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:UPCUniverse Pharmaceuticals Inc
30/03/202214h00GlobeNewswire Inc.Universe Pharmaceuticals INC Announces Strategic Partnership with Lian-Ou Health to Develop its Digital Marketing and Sales on E-Commerce PlatformsNASDAQ:UPCUniverse Pharmaceuticals Inc
22/03/202213h00GlobeNewswire Inc.Universe Pharmaceuticals INC Authorized as The International Branch of National Engineering Technology Research CenterNASDAQ:UPCUniverse Pharmaceuticals Inc
11/02/202214h01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:UPCUniverse Pharmaceuticals Inc
31/01/202214h02Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:UPCUniverse Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:UPC

Kürzlich von Ihnen besucht

BIT
Q00230
Leonteq Securities
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten